Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often
ineffective, and predictive biomarkers to guide treatment are urgently needed. We …

The use of liquid biopsies for cancer detection and management is rapidly gaining prominence
1 . Current methods for the detection of circulating tumour DNA involve sequencing …

The aryl hydrocarbon receptor (AhR) is a sensor of products of tryptophan metabolism and
a potent modulator of immunity. Here, we examined the impact of AhR in tumor-associated …

Monoclonal antibodies targeting programmed cell death protein‐1 (PD‐1) represent a new
treatment paradigm in non‐small cell lung cancer. Three phase III trials have demonstrated a …

Intratumoral heterogeneity is a critical frontier in understanding how the tumor microenvironment
(TME) propels malignant progression. Here, we deconvolute the human pancreatic …

Purpose: To perform real-time whole genome sequencing (WGS) and RNA sequencing (RNASeq)
of advanced pancreatic ductal adenocarcinoma (PDAC) to identify predictive …

Pancreatic adenocarcinoma presents as a spectrum of a highly aggressive disease in patients.
The basis of this disease heterogeneity has proved difficult to resolve due to poor tumor …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available …

Purpose: To determine the impact of basal-like and classical subtypes in advanced
pancreatic ductal adenocarcinoma (PDAC) and to explore GATA6 expression as a surrogate …